<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546582</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 3507</org_study_id>
    <nct_id>NCT03546582</nct_id>
  </id_info>
  <brief_title>SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma</brief_title>
  <acronym>KEYSTROKE</acronym>
  <official_title>KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTOG Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RTOG Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial with a safety run-in component will evaluate whether the addition of&#xD;
      pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the&#xD;
      progression-free survival for patients with recurrent or new second primary Head and Neck&#xD;
      Squamous Cell Carcinoma (HNSCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety Run-In:&#xD;
&#xD;
      To evaluate the safety of the addition of pembrolizumab (anti PD-1 immunotherapy) to&#xD;
      re-irradiation with SBRT for patients with recurrent or new second primary head and neck&#xD;
      squamous cell carcinoma (HNSCC).&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      To compare progression-free survival (PFS) for patients with recurrent or new second primary&#xD;
      head and neck squamous cell carcinoma with SBRT re-irradiation with or without pembrolizumab.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Safety Run-In: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3&#xD;
      weeks for up to 2 years.&#xD;
&#xD;
      Phase II: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up&#xD;
      to 2 years.&#xD;
&#xD;
      ARM II: Patients receive SBRT over 2 weeks. Arm II patients who experience progressive&#xD;
      disease within 2 years after the start of SBRT will be allowed to cross over to receive&#xD;
      pembrolizumab for up to 2 years.&#xD;
&#xD;
      After the completion of study treatment, patients are followed up every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Assessed up to 5 years</time_frame>
    <description>The time from randomization to the first documented progressive disease (PD) per RECIST 1.1 or death due to any cause, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed up to 5 years</time_frame>
    <description>The time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma (HNSCC)</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Anti-PD-1 targeted immunotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>High-precision radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically (histologically or cytologically) confirmed diagnosis of locoregional&#xD;
             recurrent or any new primary squamous cell carcinoma of the head and neck (including&#xD;
             of the nasopharynx or paranasal sinus) that is not amenable to curative resection.&#xD;
&#xD;
               -  Patients for whom curative resection would be medically contraindicated and/or&#xD;
                  would impose excessive surgical risk are eligible.&#xD;
&#xD;
               -  Patients who are medically and surgically resectable but for whom surgery would&#xD;
                  be associated with undue surgical morbidity are eligible.&#xD;
&#xD;
               -  For purposes of this protocol, undue surgical morbidity would include total&#xD;
                  glossectomy; carotid artery resection; laryngectomy or pharyngolaryngectomy; and&#xD;
                  major ablative resection requiring free flap reconstruction. Patients with&#xD;
                  primary tumors that can be resected without the forgoing are ineligible.&#xD;
&#xD;
               -  The principal investigators are available to review these criteria on a case by&#xD;
                  case basis if helpful to the enrolling institution.&#xD;
&#xD;
        A new primary HNSCC is defined where any one of the following criteria are met:&#xD;
&#xD;
          -  Metachronous invasive SCC developing ≥ 6 months after an index HNSCC, more than 3 cm&#xD;
             from the index lesion;&#xD;
&#xD;
          -  SCC developing in the same region as the index SCC if ≥ 36 months after the index&#xD;
             diagnosis and if within 3 cm of a site where disease was completely resected or&#xD;
             complete response was documented;&#xD;
&#xD;
          -  New SCC that is cytologically or molecularly distinct from index SCC (e.g. new HPV&#xD;
             negative SCC with prior index SCC that was HPV positive).&#xD;
&#xD;
               -  Tumor tissue testing for p16 status is required for base of tongue, soft palate,&#xD;
                  and tonsil cancer. If a p16 testing has been previously performed on an&#xD;
                  oropharynx cancer that has recurred, then repeat testing for p16 status is not&#xD;
                  required. Participants whose first cancer was an unknown primary must have p16&#xD;
                  testing from either the new primary tumor or the recurrent cancer.&#xD;
&#xD;
               -  Prior radiotherapy (RT) to the head and neck (30 Gy minimum)&#xD;
&#xD;
               -  Disease must be limited to a single site or adjacent sites that can be treated in&#xD;
                  a single contiguous target volume for which the maximum total tumor dimension&#xD;
                  (GTV) must be &lt;7.5cm. Examples of eligible patients include:&#xD;
&#xD;
                    1. A primary site recurrence in the oropharynx with a concurrent level 2 nodal&#xD;
                       mass, or a laryngeal recurrence with a level 3 nodal mass&#xD;
&#xD;
                    2. Multiple nodes in the same (level 2) or adjacent nodal levels (levels 2 and&#xD;
                       3)&#xD;
&#xD;
                    3. Skull base recurrence with a lateral pharyngeal or high level 2 node&#xD;
&#xD;
        Note: These cases will be eligible provided that the maximum total tumor dimension is&#xD;
        &lt;7.5cm. For cases in which a tumor biopsy was performed and there is a biopsy/tumor&#xD;
        debulking bed adjacent to the gross residual disease, all of the preoperative radiographic&#xD;
        abnormalities must be included in the GTV and meet the &lt;7.5cm maximal dimension criteria to&#xD;
        meet eligibility.&#xD;
&#xD;
        Note: Patients who meet these criteria only after surgical removal of a portion of the&#xD;
        patient's disease (e.g. removal of level 4 nodal mass in a patient with a tongue base&#xD;
        primary; or of a contralateral nodal mass in an N2c patient) are ineligible.&#xD;
&#xD;
          -  Patients who have undergone a recent biopsy (e.g. incisional) are eligible. Any&#xD;
             preceding surgical procedure beyond a biopsy (e.g. debulking) must be reviewed as&#xD;
             follows:&#xD;
&#xD;
               -  Patients rendered free of gross disease are not eligible.&#xD;
&#xD;
               -  Patients with gross residual disease postoperatively, must be reviewed by the&#xD;
                  Surgical Co-PI for determination of eligibility.&#xD;
&#xD;
               -  Patients eligible for study must have cutaneous wounds healed for 4-6 weeks prior&#xD;
                  to the initiation of SBRT.&#xD;
&#xD;
          -  History/physical examination within 56 days prior to entry&#xD;
&#xD;
          -  Examination by a Radiation Oncologist and Medical Oncologist within 56 days prior to&#xD;
             entry; [Note: Baseline dental assessment is strongly recommended prior to start of&#xD;
             therapy but is not required for eligibility]&#xD;
&#xD;
          -  Contrast enhanced CT or MRI, of the tumor and neck within 56 days prior to entry.&#xD;
&#xD;
          -  Chest CT scan or full body PET/CT within 56 days prior to entry; patients with&#xD;
             equivocal pulmonary nodules that are &lt; 1.5 cm, that cannot be safely biopsied, or that&#xD;
             are negative on PET/CT imaging are eligible.&#xD;
&#xD;
          -  Zubrod Performance Status of 0-1 within 28 days prior to entry.&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Trial is open to all genders&#xD;
&#xD;
          -  Hematologic: Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3, Platelets ≥ 100,000&#xD;
             cells/mm3, Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Hepatic: Total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total&#xD;
             bilirubin levels &gt; 1.5 x ULN, AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN, OR measured or calculated creatinine clearance &gt; 60 mL/min for&#xD;
             subject with creatinine levels &gt; 1.5 x institutional ULN [NOTE: Calculated creatinine&#xD;
             per institutional standard; GFR may be used in place of creatinine or CrCl]&#xD;
&#xD;
          -  Coagulation: International normalized ratio (INR), OR prothrombin time (PT), and&#xD;
             Activated partial thromboplastin time (aPTT): ≤1.5 × ULN unless participant is&#xD;
             receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of&#xD;
             intended use of anticoagulants&#xD;
&#xD;
          -  Negative serum pregnancy test within 14 days prior to entry for women of childbearing&#xD;
             potential. (Note: A pregnancy test must be repeated within 3 days prior to the&#xD;
             administration of the first dose of pembrolizumab)&#xD;
&#xD;
          -  The patient or legally authorized representative must provide study-specific informed&#xD;
             consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases.&#xD;
&#xD;
          -  Tumors that involve more than 180 degrees of the carotid artery on diagnostic CT or&#xD;
             MRI of the neck within 56 days prior to entry. Investigators are encouraged to review&#xD;
             the CT simulation imaging and ensure that tumor progression has not occurred whereby&#xD;
             patients who were initially eligible based on diagnostic imaging, would be rendered&#xD;
             ineligible based on CT simulation imaging (e.g. tumor size &gt;7.5cm, skin involvement,&#xD;
             &gt;180 degrees of carotid encasement by tumor). If this does occur, the patient should&#xD;
             be removed from the study and the Radiation Oncology Co-PIs should be notified via&#xD;
             email. Note: It is strongly recommended that CT simulation be performed prior to&#xD;
             entry.&#xD;
&#xD;
          -  Patients with gross skin involvement (i.e. tumor ulceration through the skin) are&#xD;
             excluded. Patients with tumor approaching the skin but in which the overlying skin&#xD;
             remains intact are eligible, providing that planning constraints can be achieved&#xD;
             without the use of bolus.&#xD;
&#xD;
          -  Disease that requires two or more discontiguous target volumes will be ineligible.&#xD;
             Examples of such cases include:&#xD;
&#xD;
               -  Bilateral nodal targets&#xD;
&#xD;
               -  Level 2 and level 4 nodes&#xD;
&#xD;
               -  An oropharyngeal recurrence with a low level 4 node;&#xD;
&#xD;
          -  Patients for whom the maximal total tumor dimension (GTV) is &gt;7.5cm&#xD;
&#xD;
          -  Prior radiation to primary tumor within 6 months of entry&#xD;
&#xD;
          -  Prior systemic therapy, investigational agent or investigational device within 28 days&#xD;
             of start of study treatment.&#xD;
&#xD;
          -  Surgical resection of the qualifying cancer is not permitted. (Patients who have&#xD;
             undergone biopsies are eligible). Patients without radiographically apparent gross&#xD;
             tumor are ineligible. For cases where an operation more extensive than a biopsy was&#xD;
             performed but radiographically apparent gross residual tumor remains, will be reviewed&#xD;
             by the Surgical Co-PI for determination of eligibility.&#xD;
&#xD;
          -  No concurrent treatment with other investigational agent or investigational device.&#xD;
&#xD;
          -  Prior therapy with a checkpoint inhibitor (eg anti-CTLA-4, anti-PD-1 or anti-PD-L1&#xD;
             therapy).&#xD;
&#xD;
          -  Patients with immunodeficiency, or receiving systemic steroid, or any form of&#xD;
             immunosuppressive therapy at the time of registration (e.g. history of human&#xD;
             immunodeficiency virus - HIV). Use of physiologic doses corticosteroids may be&#xD;
             approved with consultation with study chairs.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g. thyroxin, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency etc.) is not considered a&#xD;
             form of systemic therapy&#xD;
&#xD;
          -  Known active hepatitis B (positive test for virus surface antigen - HBsAg) or&#xD;
             hepatitis C virus (e.g. positive HCV RNA qualitative test).&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis.&#xD;
&#xD;
          -  Treatment with a live vaccine within 30 days of entry. Note: Seasonal influenza&#xD;
             vaccines for injection are generally inactivated flu vaccines and are allowed; however&#xD;
             intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are&#xD;
             not allowed&#xD;
&#xD;
          -  Unstable angina and or congestive heart failure requiring hospitalization in the last&#xD;
             6 months.&#xD;
&#xD;
          -  Transmural myocardial infarction within the last 6 months.&#xD;
&#xD;
          -  Active bacterial or fungal infection requiring intravenous antibiotic at the time of&#xD;
             registration; Note: If the infection resolves and the patient is on p.o. and still&#xD;
             within, the required registration timeframe, then the patient is eligible&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
             requiring hospitalization or precluding study therapy within 30 days of entry.&#xD;
&#xD;
          -  Other significant medical, surgical or psychiatric conditions or requirements for any&#xD;
             medication or treatment that in the opinion of the investigator may interfere with&#xD;
             compliance, make administration of anti-PD-L1 therapy hazardous, or obscure&#xD;
             interpretation of adverse events (AEs), such as a condition associated with frequent&#xD;
             diarrhea.&#xD;
&#xD;
          -  Pregnancy, nursing females, or women of childbearing potential and men who are&#xD;
             sexually active and not willing/able to use medically acceptable forms of&#xD;
             contraception; this exclusion is necessary because the treatment involved in this&#xD;
             study may be significantly teratogenic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart J. Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTOG Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stuart J. Wong, MD</last_name>
    <phone>414-805-4621</phone>
    <email>swong@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - North Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Ramirez</last_name>
      <phone>520-694-9056</phone>
      <email>ramirezm1@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Jared Robbins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Ames</last_name>
      <phone>813-745-3117</phone>
      <email>danielle.ames@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jimmy Caudell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Sasak</last_name>
      <phone>216-445-5256</phone>
      <email>sasakh@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Shlomo Koyfman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville, James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Roberts, RN, BSN</last_name>
      <phone>502-333-6943</phone>
      <email>teresa.roberts@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Neal Dunlap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Jose</last_name>
      <phone>617-638-8213</phone>
      <email>Annie.Jose@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Dyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gaggin, RN</last_name>
      <phone>313-916-3731</phone>
      <email>jgaggin1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Eleanor Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wade Thorstad, MD</last_name>
      <phone>314-362-8516</phone>
      <email>thorstad@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Wade Thorstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Center - UC Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaina Monroe, BS</last_name>
      <phone>513-584-7703</phone>
      <email>monroein@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Muhammad Riaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Perme</last_name>
      <phone>216-844-2512</phone>
      <email>ellen.perme@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Min Yao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Sasak</last_name>
      <phone>216-445-5256</phone>
      <email>sasakh@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Shlomo Koyfman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Elsea</last_name>
      <phone>614-685-8966</phone>
      <email>tiffany.elsea@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Dukagjin Blakaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Geier, RN</last_name>
      <phone>717-531-4300</phone>
      <email>igeier@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Mitch Machtay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Holeva</last_name>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Clump, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiffin John</last_name>
      <phone>214-645-8527</phone>
      <email>jiffin.john@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Sher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Lieb, RN</last_name>
      <phone>414-805-5153</phone>
      <email>klieb@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Lasowski</last_name>
      <phone>414-805-8375</phone>
      <email>mlasowski@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Toker</last_name>
      <phone>780-432-8711</phone>
      <email>Holly.Toker@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Brock Debenham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mom Phat, RN</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>11171</phone_ext>
      <email>mom.phat.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Phuc Felix Nguyen-Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Perna, CCRP, CCRC</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>43191</phone_ext>
      <email>marianna.perna@muhc.mcg</email>
    </contact>
    <investigator>
      <last_name>George Shenouda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Universite Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Allard</last_name>
      <phone>418-691-5790</phone>
      <email>josee.allard@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Fortin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>KEYSTROKE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

